



AGENDA ITEM

3.1.5

CTM BOARD

SCHEME OF DELEGATION REPORT

Date of meeting

29/09/2022

FOI Status

Open/Public

If closed please indicate reason

Not Applicable - Public Report

Prepared by

Owen James, Head of Corporate Finance

Presented by

Sally May, Executive Director Finance & Procurement

Approving Executive Sponsor

Executive Director of Finance & Procurement

Report purpose

FOR APPROVAL

Engagement (internal/external) undertaken to date (including receipt/consideration at Committee/group)

Committee/Group/Individuals

Date

Outcome

Audit & Risk Committee

22/08/2022

ENDORSED FOR
APPROVAL

ACRONYMS

OJEU

Official Journal of the European Union

FCPs

Financial Control Procedures

SoD

Scheme of Delegation

1. SITUATION/BACKGROUND

- 1.1 The Board are requested to approve the changes to the Scheme of Delegation appended to this report. This has been to Audit & Risk Committee on 22nd August 2022 and was endorsed for approval.

2. SPECIFIC MATTERS FOR CONSIDERATION BY THIS MEETING (ASSESSMENT)

2.1 Scheme of Delegation and Financial Control Procedures

Proposed amendments to the Scheme of Delegation are shown in **Appendix A** which outlines the existing limits and delegated authority together with the proposed changes – these are shown in tracked changes.

The Scheme of Delegation has been updated to reflect the changes in job titles due to the new organisation delivery model, moving from locality groups to care groups. The main changes are as follows:

- To change from ILG Directors to Care Group Service Directors
- To include authorisations for Deputy Chief Operating Officer
- Change the old title 'Director of Clinical Services' to Deputy Chief Operating Officer
- To include a limit of £100,000 for Deputy Chief Operating Officer for non-pay expenditure and to clarify limits for Director of Digital and Director of Governance.

Once the Scheme of Delegation has been approved, Financial Control Procedures will be updated to reflect these changes, they will be brought to future Audit & Risk Committee meetings for approval.

3. KEY RISKS/MATTERS FOR ESCALATION TO BOARD/COMMITTEE

- 3.1 N/A

4. IMPACT ASSESSMENT

Quality/Safety/Patient Experience implications	There are no specific quality and safety implications related to the activity outlined in this report.
	Governance, Leadership and Accountability



Related Health and Care standard(s)	If more than one Healthcare Standard applies please list below:
Equality Impact Assessment (EIA) completed - Please note EIAs are required for <u>all</u> new, changed or withdrawn policies and services.	No (Include further detail below)
	If yes, please provide a hyperlink to the location of the completed EIA or who it would be available from in the box below.
	If no, please provide reasons why an EIA was not considered to be required in the box below.
Legal implications / impact	There are no specific legal implications related to the activity outlined in this report.
Resource (Capital/Revenue £/Workforce) implications / Impact	There is no direct impact on resources as a result of the activity outlined in this report.
Link to Strategic Goals	Sustaining Our Future

5. RECOMMENDATION

CTM Board is asked to:

- a) **APPROVE** the amendments to the Scheme of Delegation